EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence

Pujan Engels, Andras Szolek, Sebastian Hörner, Georgios Vavouras Syrigos, Kim Hebbel, Michelle Schmidtke, Min Zhou, Maria Mateo-Tortola, Caroline Schönfeld, Sylwia Anna Stefanczyk, Katharina Wolter, Sepideh Babaei und 6 weitere

Cancer Immunology, Immunotherapy · 15.05.2025 · 74 (7)

DOI: 10.1007/s00262-025-04060-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 15.05.2025. Verfasst von Pujan Engels und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Innate Immunity, Institute of Immunology, University of Tübingen, Tübingen, Germany. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Cellular Senescence. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Volkswagen Foundation, Deutsches Konsortium für translationale Krebsforschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapy-induced senescence (TIS) is a stable cell cycle arrest in cancerous cells favoring immune control upon immune cell recruitment and activation via a senescence-associated secretory phenotype (SASP). Numerous studies have investigated the therapeutic applicability of TIS in hepatocellular carcinoma (HCC), a frequent cancer with high morbidity and mortality. Despite these efforts, a comprehensive understanding of how TIS may expose vulnerabilities specifically for immunotherapies, a potent means of cancer therapy, in HCC remains incomplete. Therefore, we conducted systematic studies to carefully characterize actionable and shared SASP- or other senescence-associated molecular parameters of TIS. We systematically compared the TIS inducers, etoposide and alisertib with a novel TIS inducer, CX5461, for their effects on SASP, surfaceome and innate immune clearance of representative human HCC cell lines. Surprisingly, all three compounds induced both metastasis surface antigens but also immunotherapeutically tractable antigens like CD95 (Fas), CD276 (B7-H3) and CD340 (Her2). This was verified in four representative HCC cell lines and publicly available datasets of HCC. Interestingly, alisertib, etoposide and CX5461 rendered senescent HCC vulnerable to be targeted by either T-cell-engaging bispecific antibodies or CAR NK cells. Collectively, our study indicates that heterogenous, but selective features of HCC senescence may be exploited by different immunotherapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsCellular SenescenceHumansPyrimidinesCell Line, TumorEtoposideAzepinesSenescence-Associated Secretory PhenotypeImmunotherapy

Stichwörter der Autor:innen

Hepatocellular carcinomaImmunologyImmunotherapySenescence

Substanzen

PyrimidinesMLN 8237EtoposideAzepines

Autor:innen und Institutionen

  • Department of Innate Immunity, Institute of Immunology, University of Tübingen, Tübingen, Germany.
  • iFIT Cluster of Excellence 2180, 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.
  • Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.
  • Department of Medical Virology, Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany.
  • DZIF Partner Site Tübingen, Tübingen, Germany.
  • Department of Medical Oncology and Pneumology, University Hospital Tübingen, Tübingen, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft
  • Volkswagen Foundation
  • Deutsches Konsortium für translationale Krebsforschung
  • Chinese Government Scholarship
  • Medizinischen Fakultät, Eberhard Karls Universität Tübingen
  • Universitätsklinikum Tübingen

Zitieren

APA

Engels, P., Szolek, A., Hörner, S., Syrigos, G. V., Hebbel, K., Schmidtke, M., Zhou, M., Mateo-Tortola, M., Schönfeld, C., Stefanczyk, S. A., Wolter, K., Babaei, S., Schindler, M., Claassen, M., Dauch, D., Zender, L., Tapía-Abellán, A., & Weber, A. N. R. (2025). Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence. Cancer Immunology, Immunotherapy, 74(7). https://doi.org/10.1007/s00262-025-04060-w

Vancouver

Engels P, Szolek A, Hörner S, Syrigos GV, Hebbel K, Schmidtke M, et al. Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence. Cancer Immunology, Immunotherapy. 2025;74(7). doi:10.1007/s00262-025-04060-w

BibTeX
@article{Engels2025,
  author = {Engels, Pujan and Szolek, Andras and Hörner, Sebastian and Syrigos, Georgios Vavouras and Hebbel, Kim and Schmidtke, Michelle and Zhou, Min and Mateo-Tortola, Maria and Schönfeld, Caroline and Stefanczyk, Sylwia Anna and Wolter, Katharina and Babaei, Sepideh and Schindler, Michael and Claassen, Manfred and Dauch, Daniel and Zender, Lars and Tapía-Abellán, Ana and Weber, Alexander N R},
  title = {Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {74},
  number = {7},
  doi = {10.1007/s00262-025-04060-w}
}
Kostenlos starten →